Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson ...
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Hosted on MSN1mon
Is Becton, Dickinson and Company (BDX) an Undervalued Stock?Oakmark Global Fund highlighted stocks like Becton, Dickinson and Company (NYSE:BDX) in the third quarter 2024 investor letter. Becton, Dickinson and Company (NYSE:BDX) develops and manufactures ...
FRANKLIN LAKES, N.J. (AP) — FRANKLIN LAKES, N.J. (AP) — Becton Dickinson and Co. (BDX) on Wednesday reported fiscal first-quarter earnings of $303 million. On a per-share basis, the Franklin ...
Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...
Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of 4% in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback